These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37976999)

  • 1. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
    ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
    Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
    Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
    Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
    Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.
    Gong J; Reimers MA
    Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H
    Int J Urol; 2024 Aug; 31(8):859-867. PubMed ID: 38722221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
    Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
    J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
    Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program.
    Park SH; Shin SJ; Rha SY; Beom SH; Seo HK; Keam B; Kim M; Hong YH; Yoon S; Lee JL
    Front Oncol; 2024; 14():1403120. PubMed ID: 38887229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
    Eto M; Lee JL; Chang YH; Gao S; Singh M; Gurney H
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e191-e203. PubMed ID: 35238147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
    Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
    Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Lapuente M; Conway D; Wood LS; Kehoe K; Carroll Bullock A; Devgan G; Burns KD
    Clin J Oncol Nurs; 2023 Jan; 27(1):71-80. PubMed ID: 37677821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
    Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
    Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
    Manitz J; Gerhold-Ay A; Kieslich P; Shah P; Mrowiec T; Tyroller K
    Cancer Med; 2024 Jun; 13(12):e7411. PubMed ID: 38924353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.